Synagis en es it fr

Synagis Brand names, Synagis Analogs

Synagis Brand Names Mixture

  • No information avaliable

Synagis Chemical_Formula

No information avaliable

Synagis RX_link

http://www.rxlist.com/cgi/generic2/palivizumab.htm

Synagis fda sheet

Synagis msds (material safety sheet)

Synagis Synthesis Reference

sequence listed in Johnson S, Oliver C, Prince GA, Hemming VG, Pfarr DS, Wang SC, Dormitzer M, O'Grady J, Koenig S, Tamura JK, Woods R, Bansal G, Couchenour D, Tsao E, Hall WC, Young JF. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis. 1997 Nov;176(5):1215-24.

Synagis Molecular Weight

No information avaliable

Synagis Melting Point

61 oC (FAB fragment), 71 oC (whole mAb) - Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000).

Synagis H2O Solubility

No information avaliable

Synagis State

Liquid

Synagis LogP

No information avaliable

Synagis Dosage Forms

Powder for solution

Synagis Indication

For treatment of respiratory diseases casued by respiratory syncytial virus

Synagis Pharmacology

Synagis exhibits neutralizing and fusion-inhibitory activity against Respiratory syncytial virus (RSV). These activities inhibit RSV replication or spread. Synagis is given to prevent the development of lower respiratory tract disease in pediatric patients.

Synagis Absorption

No information avaliable

Synagis side effects and Toxicity

No information avaliable

Synagis Patient Information

No information avaliable

Synagis Organisms Affected

No information avaliable